• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Remote electronic patient reported outcomes may have limited feasibility in older patients with cancer

bySimon PanandAlex Chan
May 14, 2024
in Chronic Disease, Oncology
Reading Time: 2 mins read
2 Minute Medicine Rewind October 21, 2019
Share on FacebookShare on Twitter

1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the use of remote electronic patient-reported outcomes for monitoring had limited feasibility.

2. Feasibility was increased when considering only the subgroup of patients who agreed to test the web application, and not including the patients who declined.

Evidence Rating Level: 2 (Good)

In recent years, the use of telemedicine has expanded dramatically. Along with this has come many questions inquiring as to the efficacy of telemedicine and its feasibility. While the use of electronic patient-reported outcomes (ePROs) have been found to improve overall survival and quality of life in patients with cancer, there is a lack of data involving the feasibility of such technologies in patients who are 75 years of age or older. This multicenter prospective study therefore sought to investigate the feasibility of ePRO follow-up in patients with cancer aged 75 years or older. 473 patients (median age, 79 years [Q1-Q3 = 77-82]) within this age range who were on anticancer therapy for active malignancy were enrolled and asked to use the web-based application, ANA, for monitoring of their symptoms throughout their treatment. Those who declined were placed in the primary failure group while those who agreed were placed in the intent to treat (ITT) group. Feasibility was defined by the number of users who were active or used ANA at least once. The overall feasibility for the study population was 26%, but was higher at 66% when examining only the ITT group. Factors involved in primary failure included socioprofessional category, as univariate and multivariate analysis determined that the ITT population was significantly from a higher socioprofessional category (P = 0.002, P = 0.009 respectively). The ITT population also felt in better general condition according to the Geriatric 8-score (P = 0.002). Overall, this study found that the use of ePROs for symptom monitoring in patients 75 years or older has limited feasibility, which may be impacted by factors influencing compliance rate such as socioprofessional category.

Click to read the study in the Journal of Clinical Oncology

Image: PD

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being

Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: artificial intelligencecancerchemotherapygeriatricsoncologytechnology
Previous Post

Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer

Next Post

Preventive angioplasty reduces adverse cardiac events in patients with non-flow-limiting vulnerable plaques

RelatedReports

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Artificial Intelligence

Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being

September 16, 2026
Artificial Intelligence

Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy

September 15, 2026
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Next Post
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Preventive angioplasty reduces adverse cardiac events in patients with non-flow-limiting vulnerable plaques

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients

Parents often unaware of adolescents’ suicidal thoughts

Reunion Neuroscience: Psychedelic Prodrug RE104 For The Treatment of Post-Partum Depression Moves Into Phase 2 Clinical Trials.

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.